Interestingly, all participants with type 2 diabetes carrying a P/LP GLIS3 variant were treated with sulfonylureas, a class of medication that stimulates the secretion of insulin by activating ATP-dependent potassium channels. This evidence concerns the gene INS and type 2 diabetes mellitus.